Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

Author's Avatar
Dec 06, 2021

Biopharmaceutical research company leverages positive data on its cannabinoid-containing mixtures to develop new cytokine release syndrome therapies